Geniposide Alleviates Amyloid-Induced Synaptic Injury by Protecting Axonal Mitochondrial Trafficking by Haijing Zhang et al.
ORIGINAL RESEARCH
published: 25 January 2017
doi: 10.3389/fncel.2016.00309
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 January 2017 | Volume 10 | Article 309
Edited by:
Hansen Wang,
University of Toronto, Canada
Reviewed by:
Stefano L. Sensi,
University of California, Irvine, USA
P. Hemachandra Reddy,
Texas Tech University Health Sciences
Center, USA
Oliver Wirths,





These authors have contributed
equally to this work.
Received: 13 November 2016
Accepted: 26 December 2016
Published: 25 January 2017
Citation:
Zhang H, Zhao C, Lv C, Liu X, Du S,
Li Z, Wang Y and Zhang W (2017)
Geniposide Alleviates
Amyloid-Induced Synaptic Injury by
Protecting Axonal Mitochondrial
Trafficking.
Front. Cell. Neurosci. 10:309.
doi: 10.3389/fncel.2016.00309
Geniposide Alleviates
Amyloid-Induced Synaptic Injury by
Protecting Axonal Mitochondrial
Trafficking
Haijing Zhang 1, 2, 3 †, Chunhui Zhao 1, 3, 4 †, Cui Lv 1, 3, 5, Xiaoli Liu 6, 7, Shijing Du 1, 3, 6, Zhi Li 1, 3, 6,
Yongyan Wang 1, 3, 4, 6 and Wensheng Zhang 1, 3, 6, 7*
1 Beijing Area Major Laboratory of Protection and Utilization of Traditional Chinese Medicine, Beijing Normal University, Beijing,
China, 2College of Life Science, Beijing Normal University, Beijing, China, 3 Engineering Research Center of Natural Medicine,
Ministry of Education, Beijing Normal University, Beijing, China, 4 Institute of Chinese Materia Medica, China Academy of
Chinese Medical Sciences, Beijing, China, 5 Laboratory of Immunology for Environment and Health, Shandong Analysis and
Test Center, Shandong Academy of Science, Jinan, China, 6College of Resources Science Technology, Beijing Normal
University, Beijing, China, 7 Engineering Research Center of Sanqi Biotechnology and Pharmaceutical, Kunming, China
Synaptic and mitochondrial pathologies are early events in the progression of
Alzheimer’s disease (AD). Normal axonal mitochondrial function and transport play
crucial roles in maintaining synaptic function by producing high levels of adenosine
triphosphate and buffering calcium. However, there can be abnormal axonal
mitochondrial trafficking, distribution, and fragmentation, which are strongly correlated
with amyloid-β (Aβ)-induced synaptic loss and dysfunction. The present study examined
the neuroprotective effect of geniposide, a compound extracted from gardenia fruit
in Aβ-treated neurons and an AD mouse model. Geniposide alleviated Aβ-induced
axonal mitochondrial abnormalities by increasing axonal mitochondrial density and length
and improving mitochondrial motility and trafficking in cultured hippocampal neurons,
consequently ameliorating synaptic damage by reversing synaptic loss, addressing
spine density and morphology abnormalities, and ameliorating the decreases in
synapse-related proteins in neurons and APPswe/PS1dE9 mice. These findings provide
new insights into the effects of geniposide administration on neuronal and synaptic
functions under conditions of Aβ enrichment.
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INTRODUCTION
Mitochondrial damage and synaptic dysfunction are early events in the pathogenesis of Alzheimer’s
disease (AD; Reddy and Beal, 2008; Hauptmann et al., 2009; Reddy, 2009; Reddy et al., 2012).
Synapses, which are the basic structural foundations of signal transduction in the central nervous
system, form connections, and transmit chemical signals among neurons (Billups and Forsythe,
2002; Li et al., 2004). Severe structural and functional damage to synapses fundamentally cause
cognitive and memory dysfunctions (Du et al., 2008; Adalbert and Coleman, 2013). Changes in the
density and morphology of synapses and dendritic spines can be detected in the cerebral cortex
and hippocampus of AD patients (DeKosky et al., 1996). Cognitive dysfunction is more strongly
correlated with synaptic loss than with senile plaques, neurofibrillary tangles, neural loss, or gliosis
(Pozueta et al., 2013).
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Synapses require a large amount of energy provided by
mitochondria, which involves mitochondrial fusion, fission,
and transport from the soma. Mitochondria are distributed
throughout neurons, including at synapses, via transfer through
axons and dendrites. The proper intracellular distribution
of the mitochondria is critical for the normal physiological
functions of neuronal cells (Cai and Tammineni, 2016), such
as neurotransmission, synaptic plasticity, and axonal outgrowth
(Li et al., 2004). Abnormal distribution and transport disorders
of the mitochondria can be observed in AD models (Stokin
et al., 2005; Du et al., 2010; Sheng and Cai, 2012; Umeda
et al., 2015) and influence the synthesis of neurotransmitters, the
release of synaptic vesicles, and calcium homeostasis, ultimately
resulting in synaptic dysfunction and adenosine triphosphate
(ATP) deficiency (Billups and Forsythe, 2002; Hollenbeck, 2005;
Verstreken et al., 2005). In this process, amyloid-β (Aβ) is
regarded as the major toxic molecule (Rui et al., 2006; Du et al.,
2010).
Aβ is transported to the mitochondria via receptor for
advanced glycation end products (RAGE; Takuma et al., 2009),
the translocase of the outer membrane (TOM) machinery
(Hansson Petersen et al., 2008; Reddy, 2009), or endoplasmic
reticulum–mitochondrial crosstalk (Hedskog et al., 2013). Aβ
progressively accumulates in the neuronal mitochondria of AD
mouse models overexpressing Aβ, AD brains, and cultured
neurons (Manczak et al., 2006, 2011; Reddy and Beal, 2008;
Reddy, 2009; Calkins et al., 2011). The accumulation of Aβ in
the mitochondria occurs before the deposition of extracellular
Aβ plaques and increases with age, particularly in synaptic
mitochondria, which are vulnerable to cumulative damage, and
induces the exaggeration of synaptic and mitochondrial injuries,
such as the overproduction of reactive oxygen species (ROS;
Manczak et al., 2006), decreased ATP, and hypometabolism
(Cardoso et al., 2004; Du and Yan, 2010). Recent studies have
shown that neuronal axonal mitochondria exhibited significantly
repressed mobility and increased fragmentation (Du et al., 2010;
Calkins and Reddy, 2011). Increasing evidence suggests that
Aβ-induced synaptic mitochondrial dysfunction contributes to
synaptic injury (Du et al., 2008, 2010; Calkins et al., 2011; Calkins
and Reddy, 2011; Fang et al., 2015). Thus, strategies to protect
synaptic mitochondria against the structural and functional
damage of Aβ may effectively prevent the deterioration of
synaptic mitochondrial dysfunction and halt AD progression.
Geniposide (Zhao et al., 2016a), an iridoid glucoside
compound isolated from gardenia fruit (Gardenia jasminoides
Ellis, Rubiaceae), attenuated the oligomeric Aβ1–42-induced
mitochondrial dysfunction by restoring ATP generation,
mitochondrial membrane potential, and cytochrome c oxidase
and caspase-3/-9 activity by reducing ROS production and
cytochrome c leakage, as well as by inhibiting apoptosis
(Lv et al., 2014a, 2015). Most studies also focused on the
neuroprotective effect of geniposide against brain diseases,
especially neurodegenerative disorders (Gao et al., 2014; Liu
et al., 2015; Zhang et al., 2015). However, the protective effect
of geniposide on axonal mitochondrial trafficking and synaptic
injury in neurons remains unclear. The outcome of this study on
cultured neurons showed that geniposide treatment significantly
alleviates Aβ-induced synaptic structural and morphological




Geniposide (Zhao et al., 2016b; purity > 98%) was purchased
from the National Institute for the Control of Pharmaceutical
and Biological Products (Beijing, China) and was free of
endotoxins. 1,1,1,3,3,3-Hexafluoro-2-propanal (HFIP) and
penicillin/streptomycin were obtained from Sigma (St. Louis,
MO, USA). Fetal bovine serum (FBS), B27, and Neurobasal-A
medium were purchased from Gibco (Waltham, MA, USA).
Mice and Drug Administration
Experimental mPrP-APPswe/PS1dE9 (APP/PS1) doubly
transgenic mice and C57BL/6 mice were purchased from Beijing
HFK Bio-Technology Co., Ltd. Nine-month-old male mice were
individually housed under a 12 h light/dark cycle at an ambient
temperature of 23 ± 1◦C and relative humidity of 55 ± 5% and
were given food and water ad libitum. Before the experiment, the
mice were housed under these conditions for 2–3 days to allow
them to adapt to the environment. APP/PS1 mice were randomly
categorized into the treatment groups or the vehicle group and
treated with either geniposide (12.5, 25, or 50 mg/kg/days; n =
15) or water (n = 15), respectively, for 3 months via intragastric
administration. Age-matched C57BL/6 mice were fed water as
the vehicle control (n = 15). Geniposide was dissolved in water
within 24 h before use. Equal volumes of liquid were given to
each group daily for 3 months before the mice were sacrificed.
All animal procedures performed in this study were approved
by the Beijing Normal University Laboratory Animal Care and
Use Committee in accordance with the National Institute of
Health “Guidelines for the Care and Use of Laboratory Animals”
(NIH Publications No. 8023, revised 1996). The mice were
sacrificed by cervical dislocation after being anesthetized. All
efforts were made to minimize the number of animals used and
their suffering.
Oligomeric Aβ1–42 Preparation
Oligomeric Aβ1–42 was prepared from commercially available
synthetic peptides (Sigma Chemical Co., St. Louis, MO, USA),
as previously described (Dahlgren et al., 2002; Yin et al., 2011).
The lyophilized peptide was resuspended in cold HFIP at a
concentration of 1 mg/mL and aliquoted into microcentrifuge
tubes to quickly obtain 0.1mg stocks. The stocks were stored
at room temperature and protected from light for 2–4 h before
the removal of HFIP under gentle vacuum, thereby leaving a
thin transparent film of peptides on the internal surface of the
tube. The stocks were stored at −20◦C. For the aggregation
protocols, HFIP-treated peptides were dissolved in anhydrous
dimethyl sulfoxide at 5 mM and diluted to 100 µM in Ham’s
F12 Nutrient Mixture (Thermo Fisher Scientific, Waltham, MA,
USA). The diluted peptides were incubated at 4◦C for 24 h to
obtain oligomeric Aβ1–42.
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Hippocampal Neuronal Culture and
Treatment
One-day-old male C57BL/6 mice were purchased from Beijing
Vital River Laboratory Animal Technology Co., Ltd., and
transported within a specific pathogen-free, air permeable, and
bacteria shield shipping box. The mice were sacrificed by cervical
dislocation.
Primary hippocampal neurons were prepared from the
hippocampi of 1 day-old (newborn) pups. The hippocampi were
dissected in cold D-Hanks solution. Tissues were collected and
washed in D-Hanks, and 0.05% (v/v) trypsin was added for
digestion at 37◦C for 20min. Digestion was terminated by adding
FBS to a final concentration of 10% (v/v). Cells were collected
by centrifugation at 800 × g for 10 min to remove the D-Hanks
solution and were then resuspended in Neurobasal-A medium
(Thermo Fisher Scientific, Waltham, MA, USA) supplemented
with 2% (v/v) B27 (Thermo Fisher Scientific).
For the various analyses, cells were plated onto 6-, 12-,
and 96-well-plates or glass-bottom dishes with four chambers
(CELLview, Greiner, Germany) (∼5 × 104 cells/mL) pre-coated
with poly-D-lysine (10 µg/mL). The cells were cultured at
37◦C and 5% CO2 until use. The initial medium was removed
after 4 h and replaced with fresh medium. After 14 days,
the medium was replaced with Neurobasal-A medium without
serum and phenol red (which affect the aggregation of Aβ). The
primary cultured hippocampal neurons were pre-incubated for
24 h in the absence or presence of geniposide (2.5, 5, or 10
µM) before adding oligomeric Aβ1–42 (200 nM) for 24 h to
assess the protective effect of geniposide on the Aβ1–42-treated
neurons.
Western Blot Assay
The brain tissue or neuron samples were lysed in 10 volumes
(w/v) of radio-immunoprecipitation assay buffer containing a
cocktail of complete protease and phosphatase inhibitors and
were centrifuged at 15,000 × g for 10 min at 4◦C. The protein
concentration of the supernatant was determined using the
BCA method. Proteins were examined by Western blot analysis
using standard protocols. Equal amounts of proteins were loaded
and resolved by 10% sodium dodecyl sulfate polyacrylamide
gel electrophoresis and transferred to nitrocellulose membranes
(Millipore, Billerica, MA, USA). The membranes were incubated
in blocking solution (5% skim milk in PBST, 20 mM Tris-
HCl, 150 mM NaCl, 0.1% Tween-20) at room temperature
for 1.5 h. The membranes were incubated and gently shaken
overnight (at 4◦C) in PBST containing 5% skim milk and
the indicated primary antibodies from among the following:
monoclonal rabbit antibodies against c-AMP response element
binding protein (CREB, 1:400, Cell Signaling, Beverley, MA,
USA), and GAPDH (1:3000, Cell Signaling); polyclonal rabbit
antibodies against phosphorylated Ca2+/calmodulin dependent
protein kinase II α (p-CaMKIIα, 1:8000, Santa Cruz, CA,
USA); and monoclonal mouse antibodies against synaptophysin
(1:500, Abcam, Cambridge, UK), CaMKIIα (1:250, Santa
Cruz), phosphorylated CREB (p-CREB, 1:400, Cell Signaling),
postsynaptic density protein-95 (PSD-95, 1:500, Abcam), and β-
actin (1:2000, Santa Cruz). After four washes with PBST, the
membranes were incubated for 1.5 h at room temperature with
the corresponding secondary antibodies. The membranes were
washed four times with PBST and detected with an infrared
imaging system (Odyssey). The intensity of the blots was analyzed
and compared using NIH ImageJ program.
ROS Measurement
ROS were measured with 2′,7′-dichlorodihydrofluorescein
diacetate (DCFH-DA). The cell-permeable DCFH-DA can be
oxidized to dichlorofluorescein (DCF) by ROS in the cytoplasm
and emit intensely fluorescence. After incubation with Aβ1–42
in the presence and absence of geniposide for 24 h, cultured
neurons were washed with PBS and incubated with 10 µM
DCFH-DA for 30 min at 37◦C in an incubator with 5% CO2.
Fluorescence images were captured using a laser-scanning
confocal microscope (TCS-SPE, Leica, Germany). Fluorescence
intensity was analyzed using NIH ImageJ program.
Axonal Mitochondrial Density Assay and
Length Measurement
Hippocampal neurons at 14 day in vitro (DIV) were used for
axonal mitochondrial density assay, and the length of these
neurons was measured after the treatments. Neurons cultured
in glass-bottom dishes with four chambers (CELLview, Greiner,
Germany) were incubated withMitoTracker Red (Thermo Fisher
Scientific, Waltham, MA, USA) at 100 nM for 20 min at 37◦C
and 5% CO2. Neurons were fixed in 4% paraformaldehyde for
20 min after being permeabilized with 0.5% Triton X-100 in
0.1% sodium citrate and blocked with 10% goat serum. Up
to 0.25 mL of anti-Tau antibody (Abcam, 1:500) was added
to each chamber, followed by incubation with goat anti-rabbit
secondary antibody (Alexa Fluor 488, Abcam, UK). Axons were
identified based on morphological characteristics. In live images,
branches that are longer and with thin and uniform diameter, as
well as sparse branching, were considered to be axons. Particles
with strong red fluorescence (compared with background) and
clear edges colocalized with axons were considered to be
mitochondria. Fluorescence images were captured using a laser-
scanning confocal microscope (TCS-SPE, Leica, Germany) and
analyzed using NIH ImageJ program.
Recording and Analysis of Axonal
Mitochondrial Trafficking
MitoTracker Green (Thermo Fisher Scientific, Waltham, MA,
USA) was used to label the mitochondria in living neurons. The
axons and mitochondria were identified using the procedure
described in Section Axonal Mitochondrial Density Assay and
Length Measurement. The proximal region of axons was selected
for time-lapse imaging analysis. Time-lapse images were captured
under an inverted laser-scanning confocal microscope (TCS-SPE,
Leica, Germany) with a stage-based chamber under 5% CO2 and
37◦C. Time-lapse image stacks composed of five images (512 ×
512 pixel) were taken every 10 s for 5 min for a total of 150
images under 40× magnification. Kymographs were generated
using the kymograph tool for ImageJ program under maximum
intensity projection. The width of the kymographs represents the
length (µm) of the imaged axon, and the height represents the
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recording time. Amitochondrion was considered to be stationary
if it remained non-mobile for the entire recording period. A
mitochondrion was considered movable only if the displacement
was more than 2 µm. The percentages of stationary and movable
mitochondria and of anterograde and retrograde mitochondrial
movement were measured separately from the corresponding
kymographs by using NIH ImageJ program. A mitochondrion
that moves from the soma toward the distal end of an axon is
considered anterograde, whereas movement from the distal end
toward the soma is considered retrograde. The average velocity
(µm/s) of all anterograde and retrograde axonal mitochondria
was calculated using the displacement of each mitochondrion.
Dendritic Spine Density Measurement and
Morphological Assay
Neurons cultured in glass-bottom dishes with four
chambers (CELLview, Greiner, Germany) were fixed in 4%
paraformaldehyde for 20 min and washed with PBS after the
neurons were incubated with 2 µM preheated CellTracker CM-
DiI (Life Technologies, Waltham, MA, USA) for 20 min at 37◦C.
LAS X software was used to control the laser-scanning confocal
microscope (TCS-SPE, Leica, Germany) equipped with a 63×
objective and excitation at 543 nm. Images were taken under the
confocal microscope, and Z-stacks were gathered at increments
of 0.67 µm. To increase the accuracy of the identification of
the surfaces of the dendrite shaft and spines, sequence images
were deconvolved to reduce point-spread functions by using the
adaptive blind 3D deconvolution method (AutoQuant X, Media
Cybermedics, Inc., Bethesda, MD) prior to analysis. The output
images were obtained with Build Neurites and Build Spines in
NeuronStudio software (CNIC, Mt. Sinai School of Medicine,
New York, USA) to mark and record all the spines on the selected
dendrites. Dendritic protrusions with a clearly identifiable neck
attached to the branch of the dendrite composed a spine.
The output data included length, neck diameter, and head
diameter of each spine, based on which the types of spines were
recognized. Spines with a spine length-to-neck diameter ratio
<2.0 were defined as of the stubby type. Spines were categorized
as mushroom type if they presented a length-to-neck diameter
ratio of more than 2.0 and a head-to-neck diameter ratio of
more than 1.3. Spines were categorized as thin type if the spines
exhibited a length-to-neck diameter ratio of more than 2.0 and
a head-to-neck diameter ratio of <1.3 (Du et al., 2014). Spine
density and morphology were measured separately for portions
of three to five selected secondary dendrites per neuron.
Neuronal Synaptic Density Analysis
Cultured hippocampal neurons were fixed in 4%
paraformaldehyde for 20 min after the neurons were
permeabilized with 0.5%Triton X-100 in 0.1% sodium citrate and
blocked with 10% goat serum. Up to 0.25 mL each of anti-MAP2
antibody (Abcam, 1:100) and anti-synaptophysin (Abcam, 1:200)
was added to each chamber, followed by incubation with goat
anti-rabbit and mouse secondary antibodies (Alexa Fluor 488,
Alexa Fluor 594, Abcam, UK) for 30 min at 37◦C. Images were
taken under a laser-scanning confocal microscope (TCS-SPE,
Leica, Germany) by using a 40× objective and excitation of 488
and 543 nm, and Z-stacks were gathered at increments of 0.67
µm. The z-stack images were compressed to a single image via
the max projection method and analyzed using NIH ImageJ
program.
Statistical Analysis
The results were processed for statistical analysis using SPSS
(version 20.0 for Windows). The results are presented as the
mean ± standard error of the mean (SEM). Statistical analyses
were performed with one-way analysis of variance, followed by
Fisher’s protected least significant difference test for post-hoc




Mitochondria are vital to the function of synapses because
they supply energy for maintenance, calcium buffering, synaptic
transmission, and vesicle release. Mitochondria are thought to be
synthesized perinuclearly. Thus, they must be transferred from
the soma to distal synapses through axons and dendrites via
mitochondrial transport and constantly reconfigured to meet
synaptic needs. Mitochondrial morphology is also dynamic and
can be regulated through fusion and fission. An elongated
morphology may confer bioenergetic advantages for ATP
generation and dispersal (Skulachev, 2001). Therefore, the effects
of geniposide on Aβ-induced abnormal axonal mitochondrial
trafficking, distribution, and morphology were analyzed. A
primary cultured hippocampal neuronal model was examined
as previously reported because of the technical limitations on
observing mitochondrial trafficking in vivo (Du et al., 2010).
Axonal processes were selected for the quantitative analysis of
mitochondrial length, density, distribution, and mobility because
of their knownmorphologic and dynamic characteristics (Banker
and Cowan, 1979; Du et al., 2010) and because of the significantly
synaptic pathology of AD.
Geniposide Attenuated Aβ1–42-Induced Axonal
Mitochondrial Fragmentation
First, axonalmitochondrial density was evaluated by counting the
mitochondria (particles positive for MitoTracker Red) in each
axonal process of the same length. As shown in Figures 1A,B,
the axonal mitochondrial density was significantly lower (∼37%)
in neurons treated with Aβ1–42 than in vehicle-treated neurons
(2.685± 0.237 vs. 1.685± 0.181 per 10 µm; p < 0.01). However,
the axonal mitochondrial density of neurons pretreated with
10µM geniposide was significantly higher than that of neurons
treated with Aβ1–42 alone (2.611 ± 0.217 vs. 1.685 ± 0.181 per
10µm; p < 0.01).
Second, the changes in mitochondrial morphology were
detected by measuring the axonal mitochondrial length.
Treatment with 200 nM oligomeric Aβ1–42 significantly
decreased the average length of axonal mitochondria compared
with hippocampal neurons treated with vehicle or geniposide
(1.117 ± 0.049 µm in Aβ1–42-treated neurons vs. 1.435 ±
0.041 µm in vehicle-treated neurons or 1.375 ± 0.023 µm in
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FIGURE 1 | Geniposide ameliorated the reduction in axonal mitochondrial density and length induced by oligomeric Aβ1–42 treatment. (A) Axonal
mitochondria from hippocampal neurons (14 DIV) were analyzed after 24 h of treatment with vehicle, oligomeric Aβ1–42 (200 nM), or oligomeric Aβ1–42+geniposide
(10 µM). The axonal mitochondrial index (numbers per 10 µm of axon) was computed from three independent experiments. **p < 0.01 vs. vehicle-treated group,
##p < 0.01 vs. Aβ-treated group. (B) Representative images of axonal mitochondrial distribution for the groups treated with vehicle, oligomeric Aβ1–42, or oligomeric
Aβ1–42+geniposide. Double fluorescent staining with MitoTracker Red (red, mitochondrial marker) and Tau (green, axonal marker) was performed. Scale bar = 10
µm. (C) Average lengths of axonal mitochondria in the three groups. *p < 0.05 vs. vehicle-treated group, #p < 0.05 vs. Aβ-treated group. (D) Distribution of axonal
mitochondrial length in the three groups. (E) Cumulative percentile of mitochondrial length in C. n = 3 independent cultures, eight axons per group.
geniposide- and Aβ1–42-treated neurons; p < 0.05; Figure 1C).
The percentage of axonal mitochondria <0.5 µm in length in
neurons exposed to Aβ was significantly higher than in neurons
treated with vehicle or geniposide (Figure 1D), whereas the
percentage of mitochondria more than 2.0 µm long decreased.
Cumulative data indicated a leftward shift in the mitochondrial
length of Aβ1–42-treated neurons (Figure 1E).
Geniposide Ameliorated the Aβ1–42-Induced
Impairment of Axonal Mitochondrial Trafficking
Third, mitochondrial trafficking within hippocampal axonal
processes was investigated. The percentage of stationary
mitochondria among total mitochondria in Aβ1–42-treated
neurons was significantly higher (by ∼15%) that that in the
neurons treated with vehicle (60.028± 2.154 vs. 74.695± 3.363%;
p < 0.01, Figure 2A), and geniposide treatment produced a
partial recovery of the percentage of stationary mitochondria
(63.319 ± 2.761%; p < 0.05; Figure 2A). The percentage
of mitochondria moving in either direction (anterograde
and retrograde) in Aβ1–42-treated neurons was significantly
lower than in vehicle-treated and geniposide-treated neurons
(Figures 2A,C). The percentage of anterograde mitochondria
amongmovable mitochondria in Aβ1–42-treated neurons slightly
decreased compared with neurons treated with vehicle or
geniposide (45.63 ± 2.324% in Aβ1–42-treated neurons vs. 56.3
± 3.24% in vehicle-treated neurons or 56.55 ± 3.323% in
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FIGURE 2 | Geniposide ameliorated the abnormal axonal trafficking of mitochondria induced by oligomeric Aβ1–42 treatment. Axons from hippocampal
neurons at 14 DIV were analyzed after 24 h of treatment with vehicle, oligomeric Aβ1–42 (200 nM), or oligomeric Aβ1–42+geniposide (10 µM). Fluorescent staining
with MitoTracker Green (mitochondrial marker) was performed. (A) Percentages of stationary, movable, anterograde-moving, and retrograde-moving mitochondria
were calculated compared with the numbers of total mitochondria. **p < 0.01 vs. vehicle-treated group, #p < 0.05 vs. Aβ-treated group. (B) Percentages of
anterograde-moving and retrograde-moving mitochondria were calculated compared with the total numbers of movable mitochondria. *p < 0.05 vs. vehicle-treated
group, #p < 0.05 vs. Aβ-treated group. (C) Calculations were based on analysis of kymographs. Representative kymographs of the axonal mitochondrial movement
in the three experimental groups. Scale bar = 10 µm. (D) Average velocity of anterograde and retrograde transport of mitochondria for all movable mitochondria
(µm/min) is shown. *p < 0.05 vs. vehicle-treated group, #p < 0.05 vs. Aβ-treated group. (E,F) Cumulative percentile of anterograde or retrograde mitochondrial
velocity in D. n = 4 independent cultures, six axons per group.
geniposide- and Aβ1–42-treated neurons; p < 0.05; Figure 2B).
By contrast, the percentage of retrograde mitochondria increased
in Aβ1–42-treated neurons.
Fourth, the velocity of mitochondrial movement within
axons was measured. Aβ1–42 treatment produced a greater
detrimental effect on anterograde mitochondrial movement
velocity than retrograde (Figure 2D). Aβ1–42 treatment
decreased the anterograde velocity of axonal mitochondria by
18% (16.996 ± 1.18 µm/min in Aβ1–42-treated neurons vs.
13.965 ± 0.98µm/min in vehicle-treated neurons; p < 0.05;
Figures 2D,E), whereas the geniposide treatment decreased the
toxicity of Aβ1–42 on the anterograde mitochondrial velocity
(16.996 ± 1.18 µm/min in Aβ1–42-treated neurons vs. 17.134
± 0.961 µm/min in geniposide- and Aβ1–42-treated neurons; p
< 0.05). However, the retrograde transport velocity of axonal
mitochondria did not differ significantly among the three groups
(Figures 2D,F). Cumulative data displayed a leftward shift in the
anterograde mitochondrial velocity (Figure 2E) but not in the
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retrograde mitochondrial velocity (Figure 2F) of Aβ1–42-treated
neurons.
Geniposide Attenuates Aβ1–42-Induced Neurites ROS
Elevation
The mitochondrial ROS level was evaluated by measuring the
fluorescence intensity of DCF within neurites. As shown in
Figures 3A,B, the fluorescence intensity of DCF within the
neurites of Aβ1–42-treated hippocampal neurons significantly
increased (by ∼48%), unlike the vehicle-treated or geniposide-
treated neurons (1.0 ± 0.075 in Aβ1–42-treated neurons
vs. 1.478 ± 0.097 in vehicle-treated neurons or 1.050 ±
0.065 in geniposide- and Aβ1–42-treated neurons; p < 0.01;
Figure 3B). These results suggested that geniposide treatment
significantly reduced the Aβ-induced increase in ROS in neurite
mitochondria.
These data indicate that geniposide plays a protective
role against the increased mitochondrial fragmentation, ROS
elevation, and defective axonal mitochondrial trafficking induced
by oligomeric Aβ1–42 in neurons.
Geniposide Alleviated Aβ1–42-Induced
Synaptic Damage in Cultured Neurons and
an AD Model
Axonal mitochondria are dynamic organelles, and their
dynamics, trafficking, and docking are critical to maintain
synaptic function and plasticity. The impairment of axonal
mitochondrial may lead to synaptic loss and dysfunction. Various
lines of evidence indicate that synaptic loss and deactivation
are the biological bases of AD, and the accumulation of Aβ
is an early event associated with synaptic and mitochondrial
damage in AD. Thus, the density of synapses, the morphology of
dendritic spines, and the levels of synapse-related proteins
were analyzed to assess the contributions of abnormal
mitochondrial fragmentation and trafficking to synaptic loss and
dysfunction.
Geniposide Protected against Aβ1–42-Induced
Synaptic Loss
Synaptic density was measured by counting synaptophysin-
positive clusters (green) on dendrites in order to determine the
protective effect of geniposide on oligomeric Aβ1–42-induced
synaptic loss. As shown in Figure 4A, there were significantly
fewer synaptophysin-positive clusters in Aβ-treated neurons
than in vehicle- or geniposide-treated neurons. The density of
synapses in Aβ1–42-treated neurons was significantly lower (by
∼49%) than in the vehicle-treated neurons (1.001 ± 0.041 per
micron vs. 0.509 ± 0.030 per micron; p < 0.001, Figure 4B),
whereas neurons pre-treated with geniposide (10 µM) showed a
higher density of synapses than the Aβ1–42-treated group (0.985
± 0.040 per micron vs. 0.509± 0.030 per micron; p < 0.001).
Geniposide Rescued Aβ1–42-Induced Abnormal
Spine Density and Morphology
Dendritic spine density and morphology significantly changed in
transgenic AD mouse models (Perez-Cruz et al., 2011; Penazzi
et al., 2016); therefore, the spine phenotypes in cultured primary
hippocampal neurons were investigated using CellTracker CM-
DiI, and dendritic spines were categorized into three groups
(mushroom, stubby, and thin).
First, the spine density was examined. As expected, Aβ1–42
treatment significantly decreased the spine density on dendrites,
whereas geniposide-treated neurons showed notable recovery
(7.95 ± 0.405 per 10 µm in Aβ1–42-treated neurons vs. 10.825
± 0.994 per 10 µm in vehicle-treated neurons or 10.575 ±
0.826 per 10 µm in geniposide- and Aβ1–42-treated neurons;
p < 0.05; Figure 5A). Cumulative data showed a substantial
leftward shift in the spine density of Aβ1–42-treated neurons
(Figure 5B).
Subsequently, the spine morphology was evaluated in terms
of spine length and classification (mushroom, stubby, and
thin). The morphology of the spines from Aβ1–42-treated
neurons changed markedly from that of vehicle-treated neurons:
the former appeared shorter and more stubby, with fewer
FIGURE 3 | Geniposide treatment attenuates the oligomeric Aβ-induced increase in neuritic ROS. (A) Representative images of DCF staining of
hippocampal neurites treated with vehicle, oligomeric Aβ1–42 (200 nM), or oligomeric Aβ1–42+geniposide (10 µM). Scale bar = 10 µm. (B) Quantification of DCF
intensity in (A). The intensity of DCF-labeled neurites was significantly increased in neurons treated with oligomeric Aβ1–42 for 24 h, while the geniposide treatment
dramatically reduced the Aβ-induced ROS elevation. **p < 0.01 vs. vehicle-treated group, ##p < 0.01 vs. Aβ-treated group. n = 4 independent cultures.
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FIGURE 4 | Effect of geniposide on Aβ-induced synaptic loss. Cultured hippocampal neurons at 14 DIV were analyzed after 24 h of treatment with vehicle,
oligomeric Aβ1–42 (200 nM), or oligomeric Aβ1–42+geniposide (10 µM). Immunostaining with MAP2 (neuronal marker) and synaptophysin (synaptic marker) was
performed. (A) Representative images for neurons and synapses treated with vehicle, oligomeric Aβ1–42, or oligomeric Aβ1–42+geniposide. Double immunostaining
with MAP2 and synaptophysin. Scale bar = 10 µm. (B) Numbers of synaptophysin-positive clusters per micron of dendrites were significantly increased in
Aβ1–42+geniposide-treated neurons compared with Aβ1–42-treated neurons. ***p < 0.001 vs. vehicle-treated group,
###p < 0.001 vs. Aβ-treated group. n = 4
independent cultures, eight neurons per group.
FIGURE 5 | Geniposide rescued the Aβ1–42-induced abnormal spine density and morphology. Dendrites from hippocampal neurons at 14 DIV were analyzed
after 24 h of treatment with vehicle, oligomeric Aβ1–42 (200 nM), or oligomeric Aβ1–42+geniposide (10 µM). Fluorescent staining with CellTracker CM-DiI was
performed. (A) Quantification of total spine density per 10 µm of dendrite. (B) Cumulative percentile of spine density in (A). (C) Average lengths of all spines in the
three groups. (D) Percentages of the three spine types (mushroom, thin, and stubby) in total spines. (E) Average head diameter of mushroom spines. (F) Cumulative
percentile of mushroom head diameter in (E). (G) Representative images of DiI-labeled dendritic segments. Scale bar = 5 µm. *P < 0.05 vs. vehicle-treated group,
#p < 0.05 vs. Aβ-treated group. n = 4 independent cultures, eight neurons per group.
mushroom-type spines than the latter (Figure 5G). Calculation
of the average length of spines showed that Aβ1–42 treatment
significantly decreased the spine length (by ∼20%), whereas
geniposide treatment reversed this pattern (Figure 5C). The
quantitative analysis of dendritic spines in Aβ1–42-treated
neurons showed that the percentage of mushroom-like spines
significantly decreased (25.476 ± 3.308% in Aβ1–42-treated
neurons vs. 40.129± 3.776% in vehicle-treated neurons or 37.977
± 2.052% in geniposide- and Aβ1–42-treated neurons; p < 0.05;
Figures 5D,G), but the percentage of stubby-like spines increased
(36.548± 2.957% in Aβ1–42-treated neurons vs. 23.641± 1.755%
in vehicle-treated neurons or 26.206 ± 2.268% in geniposide-
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and Aβ1–42-treated neurons; p < 0.05; Figures 5D,G). However,
pretreatment with geniposide almost completely reversed the
deleterious effect of Aβ1–42 on the percentages of stubby
and mushroom spines. Geniposide considerably increased the
averagemushroom head diameter compared with Aβ1–42-treated
neurons (1.152 ± 0.102 vs. 0.735 ± 0.043 µm; p < 0.05;
Figure 5E). The plots of cumulative percentage curves clearly
displayed a leftward shift in the mushroom head diameter
of Aβ1–42-treated neurons (Figure 5F). These data indicated
that geniposide treatment significantly preserved dendritic spine
density and morphology, which may play a protective role in
synaptic function.
Geniposide Ameliorated the Decrease in
Synapse-Related Proteins in Cultured Neurons and
Mice
Synaptic plasticity is widely thought to be the basis of
learning and memory formation. Synapse-related proteins
are the foundation of synaptic plasticity. To investigate the
effect of geniposide on the expression of synapse-related
proteins, the levels of specific synaptic proteins in cultured
primary hippocampal neurons were examined. The levels of
synapse-related proteins significantly decreased in Aβ1–42-
treated neurons relative to vehicle-treated neurons. As shown
in Figure 6, the levels of p-CaMKIIα/CaMKIIα, p-CREB/CREB,
synaptophysin, and PSD-95 in Aβ1–42-treated neurons were
markedly lower than those in vehicle-treated neurons and
significantly increased in neurons treated with various doses
of geniposide (2.5, 5.0, and 10.0 µM geniposide; Figure 6).
The expression of synapse-related proteins in the hippocampi
of C57 and APP/PS1 (overexpressing Aβ) mice was examined
further. Consistent with the data in cultured neurons, these
results showed that the expression levels of p-CaMKII/CaMKIIα,
p-CREB/CREB, synaptophysin, and PSD-95 were lower in
vehicle-treated APP/PS1 mice than in vehicle-treated WT mice.
Geniposide treatment (12.5, 25, and 50 mg/kg) of APP/PS1 mice
also significantly increased the levels of the above proteins in
a dose-dependent manner (Figure 7). These data indicate that
the application of geniposide protects the expression of synapse-
related proteins against the neurotoxic effects of Aβ in neurons
and APP/PS1 mice.
DISCUSSION
There are evidence suggest that geniposide have multifaceted
neuroprotective effects, such as ameliorating cholinergic deficit
(Zhao et al., 2016b), increasing the expression of insulin-
degrading enzyme (Zhang et al., 2015) and attenuating
Aβ accumulation (Lv et al., 2015), inhibiting the signaling
pathway of RAGE-MAPK and suppressing the production
of proinflammatory mediators (Lv et al., 2014b, 2015), and
protecting mitochondria by recovering ATP generation and
mitochondrial membrane potential (Lv et al., 2014a; Zhao et al.,
2016a). However, the protective effect of geniposide on Aβ
induced mitochondrial transport and synaptic injury remains
unclear.
The protective effect of geniposide against oligomeric Aβ1–42
in primary cultured hippocampal neurons was investigated
in the current study. In consideration of the influence of
overproduction of amyloid precusor protein (APP) and its
metabolites in APP transgenic mice’s neurons, we investigated
the toxicity effect of Aβ by adding exogenous oligomeric
Aβ1–42. Evidence suggests that RAGE mediates the transport
of Aβ peptides across the cytomembrane from extracellular to
intracellular (Deane et al., 2003; Takuma et al., 2009; Candela
et al., 2010), including mitochondrial localization. Moreover, Aβ
can be transported to the mitochondria via the TOM machinery
and ER-mitochondrial crosstalk (Hansson Petersen et al., 2008;
Hedskog et al., 2013).
In the present study, we demonstrate that geniposide protects
cultured primary hippocampal neurons from the Aβ-induced
impairment of axonal mitochondrial transport by improving
axonal mitochondrial morphology, motility, and distribution,
as well as rescuing anterograde mitochondrial movement, thus
alleviating Aβ-induced synaptic injury by increasing the numbers
of synapses and dendritic spines and the levels of synapse-related
proteins, as well as attenuating the increase in ROS.
Axonal mitochondrial transport and synaptic mitochondrial
distribution play crucial roles in synaptogenesis, synaptic
transmission, and synaptic plasticity (Chang et al., 2006).
Abnormal synaptic mitochondrial mobility and dynamics
are responsible for synaptic failure. Considering the critical
role of synaptic failure and neuronal dysfunction in AD
pathogenesis, studies have investigated the mechanisms of
synaptic mitochondrial perturbation that contribute to synaptic
dysfunction (Du et al., 2008, 2010). These studies indicated
that Aβ-induced abnormal axonal mitochondrial trafficking
and synaptic mitochondrial dysfunction are responsible for the
synaptic injury in AD.
Presynaptic terminals require mitochondria to handle
calcium buffering, power the plasma membrane Ca2+-ATPase,
and release Ca2+ to maintain post-tetanic potentiation
(Medler and Gleason, 2002). Furthermore, synthesis of
neurotransmitters, release of synaptic vesicles, outgrowth
of axonal, and maintenance of synaptic plasticity also need
mitochondria to supply high levels of ATP (Dillon and Goda,
2005). Therefore, decreased mitochondrial transport in axons
likely impairs the delivery of organelles to synapses. Aβ has
been reported to cause rapid and severe impairment of synaptic
mitochondrial distribution and axonal mitochondrial mobility
and thus to increase axonal mitochondrial fragmentation (Rui
et al., 2006; Du et al., 2010; Calkins et al., 2011; Manczak
et al., 2011). The current results regarding mitochondrial
morphology and mobility indicated that geniposide ameliorated
the effects of Aβ treatment that were induced by abnormal
mitochondrial morphology and trafficking in axons by increasing
the mitochondrial density and length and the proportions of
movable and anterograde-transported mitochondria, as well as
the average velocity of movable axonal mitochondria. These
data suggest that geniposide may protect synaptic mitochondrial
function from Aβ-induced impairment at an early stage.
Aβ-induced axonal and synaptic mitochondrial dysfunction
is accompanied by synaptic degradation and is exhibited as
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FIGURE 6 | Geniposide alleviated the decrease in synapse-related proteins in cultured primary hippocampal neurons. (A–D) Western blot analysis of
phospho-CaMKIIα and total-CaMKIIα (A), phospho-CREB and total-CREB (B), PSD-95 (C), synaptophysin (SYN) (D), and GAPDH in hippocampal neurons treated
with the indicated concentrations of oligomeric Aβ1–42 or geniposide. Western blot of synaptophysin, PSD-95, and GAPDH were performed in the same membrane,
therefore they share the same loading control (GAPDH). Quantification of p-CaMKIIα/CaMKIIα (A) p-CREB/CREB (B), PSD-95/GAPDH (C), and
synaptophysin/GAPDH (D) was performed with the values from vehicle-treated neurons set as 1.0. Data are presented as the mean ± SEM. n = 4 independent
cultures. NS, non-significant.
the decrease of synapse-related proteins, the loss of dendritic
spines and synapses, and morphological changes to spines.
Synapse-related proteins constitute the structural and functional
foundation of synapses. However, the expression levels of
synapse-related proteins, such as synaptophysin, PSD-95, p-
CaMKII, and p-CREB, are significantly decreased in the cortex
and hippocampus of AD patients and of an AD mouse model
(Gylys et al., 2004; Almeida et al., 2005; Zeng et al., 2015).
Moreover, synaptic loss is the most severe condition of synaptic
injury, and it manifests as the loss of dendritic spines and
synapses in the brains of a transgenic ADmousemodel and of AD
patients. The density of dendritic spines significantly decreased
in the cortex and hippocampus of several ADmodels (Yang et al.,
2011; Du et al., 2014; Price et al., 2014), as well as in cultured
primary hippocampal or cortical neurons treated with Aβ in vitro
(Jo et al., 2011; Chen et al., 2015). In conclusion, the axonal and
synaptic mitochondria are vulnerable and susceptible to various
types of damage, leading to the synaptic degradation in AD. In
the present study, geniposide-treatment significantly alleviated
Aβ-induced synaptic injury by protecting the expression levels
of synapse-related proteins, the density of dendritic spines and
synapses, and the morphology of spines. Similar results were
obtained for the expression of synapse-related proteins in the
hippocampi of APP/PS1 mice.
In summary, the results demonstrated that geniposide
protected primary neurons fromAβ-induced oxidative stress and
from the acute impairment of axonal mitochondrial trafficking
and morphology. This protective effect is associated with
structural and functional changes in synapses. These findings
indicate that axonal and synaptic mitochondria are vulnerable
and susceptible to injury by Aβ at a low concentration, whereas
geniposide can alleviate such injury. Thus, geniposide is a
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FIGURE 7 | Geniposide alleviated the decrease in synapse-related proteins in the hippocampi of APP/PS1 mice. (A–D) Western blot analysis of
phospho-CaMKIIα and total-CaMKIIα (A), phospho-CREB, and total-CREB (B), PSD-95 (C), synaptophysin (D), and GAPDH in the hippocampi of indicated group of
mice with/without geniposide administration. Western blot of synaptophysin, PSD-95 and GAPDH were performed in the same membrane, therefore they share the
same loading control (GAPDH). Quantification of p-CaMKIIα/CaMKIIα (A) p-CREB/CREB (B), PSD-95/GAPDH (C), and synaptophysin/GAPDH (D) was performed
using the values from vehicle-treated WT mice as 1.0. Data are presented as the mean ± SEM. n = 6 mice for each group. Gp, mice treated with geniposide. NS,
non-significant.
potential therapeutic agent that can be used to halt and prevent
AD progression at an early stage.
AUTHOR CONTRIBUTIONS
HZ, CZ, YW, and WZ designed the research; CZ, HZ, SD, CL,
and ZL performed the research and analyzed data; and CZ, HZ,
andWZ wrote the paper. All authors read and approved the final
manuscript.
ACKNOWLEDGMENTS
This work was supported by grants from the National
Natural Science Foundation of China (No. 81274118), the
Key New Drug Creation and Development Program of China
(No. 2012ZX09103-201), the Fundamental Research Funds
for the Central Universities (No. 2015KJJCA05). Thanks
to Fang Fang for providing language help and writing
assistance.
REFERENCES
Adalbert, R., and Coleman, M. P. (2013). Review: axon pathology in age-
related neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 39, 90–108.
doi: 10.1111/j.1365-2990.2012.01308.x
Almeida, C. G., Tampellini, D., Takahashi, R. H., Greengard,
P., Lin, M. T., Snyder, E. M., et al. (2005). Beta-amyloid
accumulation in APP mutant neurons reduces PSD-95 and GluR1
in synapses. Neurobiol. Dis. 20, 187–198. doi: 10.1016/j.nbd.2005.
02.008
Frontiers in Cellular Neuroscience | www.frontiersin.org 11 January 2017 | Volume 10 | Article 309
Zhang et al. Synaptic Protective Effects of Geniposide
Banker, G. A., and Cowan, W. M. (1979). Further observations on hippocampal
neurons in dispersed cell culture. J. Comp. Neurol. 187, 469–493.
doi: 10.1002/cne.901870302
Billups, B., and Forsythe, I. D. (2002). Presynaptic mitochondrial calcium
sequestration influences transmission at mammalian central synapses. J.
Neurosci. 22, 5840–5847.
Cai, Q., and Tammineni, P. (2016). Alterations in mitochondrial quality control in
Alzheimer’s disease. Front. Cell. Neurosci. 10:24. doi: 10.3389/fncel.2016.00024
Calkins, M. J., Manczak, M., Mao, P., Shirendeb, U., and Reddy, P. H.
(2011). Impaired mitochondrial biogenesis, defective axonal transport of
mitochondria, abnormal mitochondrial dynamics and synaptic degeneration
in a mouse model of Alzheimer’s disease. Hum. Mol. Genet. 20, 4515–4529.
doi: 10.1093/hmg/ddr381
Calkins, M. J., and Reddy, P. H. (2011). Amyloid beta impairs
mitochondrial anterograde transport and degenerates synapses in
Alzheimer’s disease neurons. Biochim. Biophys. Acta 1812, 507–513.
doi: 10.1016/j.bbadis.2011.01.007
Candela, P., Gosselet, F., Saint-Pol, J., Sevin, E., Boucau, M. C., Boulanger,
E., et al. (2010). Apical-to-basolateral transport of amyloid-beta peptides
through blood-brain barrier cells is mediated by the receptor for advanced
glycation end-products and is restricted by P-glycoprotein. J. Alzheimers Dis.
22, 849–859. doi: 10.3233/JAD-2010-100462
Cardoso, S. M., Santana, I., Swerdlow, R. H., and Oliveira, C. R. (2004).
Mitochondria dysfunction of Alzheimer’s disease cybrids enhances Abeta
toxicity. J. Neurochem. 89, 1417–1426. doi: 10.1111/j.1471-4159.2004.02438.x
Chang, D. T., Honick, A. S., and Reynolds, I. J. (2006). Mitochondrial trafficking
to synapses in cultured primary cortical neurons. J. Neurosci. 26, 7035–7045.
doi: 10.1523/JNEUROSCI.1012-06.2006
Chen, J., Li, S., Sun, W., and Li, J. (2015). Anti-diabetes drug
pioglitazone ameliorates synaptic defects in AD transgenic mice by
inhibiting cyclin-dependent kinase5 activity. PLoS ONE 10:e0123864.
doi: 10.1371/journal.pone.0123864
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A.,
and LaDu, M. J. (2002). Oligomeric and fibrillar species of amyloid-beta
peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046–32053.
doi: 10.1074/jbc.M201750200
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., et al.
(2003). RAGE mediates amyloid-beta peptide transport across the blood-brain
barrier and accumulation in brain. Nat. Med. 9, 907–913. doi: 10.1038/nm890
DeKosky, S. T., Scheff, S. W., and Styren, S. D. (1996). Structural correlates
of cognition in dementia: quantification and assessment of synapse change.
Neurodegeneration 5, 417–421. doi: 10.1006/neur.1996.0056
Dillon, C., and Goda, Y. (2005). The actin cytoskeleton: integrating
form and function at the synapse. Annu. Rev. Neurosci. 28, 25–55.
doi: 10.1146/annurev.neuro.28.061604.135757
Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A. A., McKhann, G. M., et al. (2008).
Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation
and ameliorates learning and memory in Alzheimer’s disease. Nat. Med. 14,
1097–1105. doi: 10.1038/nm.1868
Du, H., Guo, L., Wu, X., Sosunov, A. A., McKhann, G. M., Chen, J. X., et al.
(2014). Cyclophilin D deficiency rescues Abeta-impaired PKA/CREB signaling
and alleviates synaptic degeneration. Biochim. Biophys. Acta 1842(12 Pt A),
2517–2527. doi: 10.1016/j.bbadis.2013.03.004
Du, H., Guo, L., Yan, S., Sosunov, A. A., McKhann, G. M., and Yan, S. S. (2010).
Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model.
Proc. Natl. Acad. Sci. U.S.A. 107, 18670–18675. doi: 10.1073/pnas.1006586107
Du, H., and Yan, S. S. (2010). Mitochondrial medicine for neurodegenerative
diseases. Int. J. Biochem. Cell Biol. 42, 560–572. doi: 10.1016/j.biocel.2010.
01.004
Fang, D., Wang, Y., Zhang, Z., Du, H., Yan, S., Sun, Q., et al. (2015).
Increased neuronal PreP activity reduces Abeta accumulation, attenuates
neuroinflammation and improves mitochondrial and synaptic function
in Alzheimer disease’s mouse model. Hum. Mol. Genet. 24, 5198–5210.
doi: 10.1093/hmg/ddv241
Gao, C., Liu, Y., Jiang, Y., Ding, J., and Li, L. (2014). Geniposide ameliorates
learning memory deficits, reduces tau phosphorylation and decreases apoptosis
via GSK3β pathway in streptozotocin-induced alzheimer rat model. Brain
Pathol. 24, 261–269. doi: 10.1111/bpa.12116
Gylys, K. H., Fein, J. A., Yang, F., Wiley, D. J., Miller, C. A., and Cole, G. M. (2004).
Synaptic changes in Alzheimer’s disease: increased amyloid-beta and gliosis in
surviving terminals is accompanied by decreased PSD-95 fluorescence. Am. J.
Pathol. 165, 1809–1817. doi: 10.1016/S0002-9440(10)63436-0
Hansson Petersen, C. A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov,
P. F., Alafuzoff, I., et al. (2008). The amyloid beta-peptide is imported
into mitochondria via the TOM import machinery and localized to
mitochondrial cristae. Proc. Natl. Acad. Sci. U.S.A. 105, 13145–13150.
doi: 10.1073/pnas.0806192105
Hauptmann, S., Scherping, I., Drose, S., Brandt, U., Schulz, K. L., Jendrach, M.,
et al. (2009). Mitochondrial dysfunction: an early event in Alzheimer pathology
accumulates with age in AD transgenic mice. Neurobiol. Aging 30, 1574–1586.
doi: 10.1016/j.neurobiolaging.2007.12.005
Hedskog, L., Pinho, C. M., Filadi, R., Ronnback, A., Hertwig, L., Wiehager, B.,
et al. (2013). Modulation of the endoplasmic reticulum-mitochondria interface
in Alzheimer’s disease and related models. Proc. Natl. Acad. Sci. U.S.A. 110,
7916–7921. doi: 10.1073/pnas.1300677110
Hollenbeck, P. J. (2005). Mitochondria and neurotransmission: evacuating the
synapse. Neuron 47, 331–333. doi: 10.1016/j.neuron.2005.07.017
Jo, J., Whitcomb, D. J., Olsen, K.M., Kerrigan, T. L., Lo, S. C., Bru-Mercier, G., et al.
(2011). Aβ1−42 inhibition of LTP is mediated by a signaling pathway involving
caspase-3, Akt1 and GSK-3β. Nat. Neurosci. 14, 545–547. doi: 10.1038/
nn.2785
Li, Z., Okamoto, K., Hayashi, Y., and Sheng, M. (2004). The importance of
dendritic mitochondria in the morphogenesis and plasticity of spines and
synapses. Cell 119, 873–887. doi: 10.1016/j.cell.2004.11.003
Liu, W., Li, G., Holscher, C., and Li, L. (2015). Neuroprotective effects of
geniposide from Alzheimer’s disease pathology. Rev. Neurosci. 26, 371–383.
doi: 10.1515/revneuro-2015-0005
Lv, C., Liu, X., Liu, H., Chen, T., and Zhang, W. (2014a). Geniposide attenuates
mitochondrial dysfunction and memory deficits in APP/PS1 transgenic mice.
Curr. Alzheimer Res. 11, 580–587. doi: 10.2174/1567205011666140618095925
Lv, C., Wang, L., Liu, X., Cong, X., Yan, S. S., Wang, Y., et al. (2014b). Geniposide
attenuates oligomeric Aβ(1-42)-induced inflammatory response by targeting
RAGE-dependent signaling in BV2 cells. Curr. Alzheimer Res. 11, 430–440.
doi: 10.2174/1567205011666140514111204
Lv, C., Wang, L., Liu, X. L., Yan, S. J., Yan, S. S., Wang, Y. Y., et al. (2015). Multi-
faced neuroprotective effects of geniposide depending on the RAGE-mediated
signaling in an Alzheimer mouse model. Neuropharmacology 89, 175–184.
doi: 10.1016/j.neuropharm.2014.09.019
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., and Reddy,
P. H. (2006). Mitochondria are a direct site of A beta accumulation in
Alzheimer’s disease neurons: implications for free radical generation and
oxidative damage in disease progression. Hum. Mol. Genet. 15, 1437–1449.
doi: 10.1093/hmg/ddl066
Manczak, M., Calkins, M. J., and Reddy, P. H. (2011). Impaired mitochondrial
dynamics and abnormal interaction of amyloid beta withmitochondrial protein
Drp1 in neurons from patients with Alzheimer’s disease: implications for
neuronal damage. Hum. Mol. Genet. 20, 2495–2509. doi: 10.1093/hmg/ddr139
Medler, K., and Gleason, E. L. (2002). Mitochondrial Ca2+ buffering regulates
synaptic transmission between retinal amacrine cells. J. Neurophysiol. 87,
1426–1439. doi: 10.1152/jn.00627.2001
Penazzi, L., Tackenberg, C., Ghori, A., Golovyashkina, N., Niewidok, B., Selle,
K., et al. (2016). Abeta-mediated spine changes in the hippocampus are
microtubule-dependent and can be reversed by a subnanomolar concentration
of the microtubule-stabilizing agent epothilone D. Neuropharmacology 105,
84–95. doi: 10.1016/j.neuropharm.2016.01.002
Perez-Cruz, C., Nolte, M. W., van Gaalen, M. M., Rustay, N. R., Termont, A.,
Tanghe, A., et al. (2011). Reduced spine density in specific regions of CA1
pyramidal neurons in two transgenic mouse models of Alzheimer’s disease. J.
Neurosci. 31, 3926–3934. doi: 10.1523/JNEUROSCI.6142-10.2011
Pozueta, J., Lefort, R., and Shelanski, M. L. (2013). Synaptic changes
in Alzheimer’s disease and its models. Neuroscience 251, 51–65.
doi: 10.1016/j.neuroscience.2012.05.050
Price, K. A., Varghese, M., Sowa, A., Yuk, F., Brautigam, H., Ehrlich, M. E.,
et al. (2014). Altered synaptic structure in the hippocampus in a mouse model
of Alzheimer’s disease with soluble amyloid-beta oligomers and no plaque
pathology.Mol. Neurodegener. 9:41. doi: 10.1186/1750-1326-9-41
Frontiers in Cellular Neuroscience | www.frontiersin.org 12 January 2017 | Volume 10 | Article 309
Zhang et al. Synaptic Protective Effects of Geniposide
Reddy, P. H. (2009). Amyloid beta, mitochondrial structural and
functional dynamics in Alzheimer’s disease. Exp. Neurol. 218, 286–292.
doi: 10.1016/j.expneurol.2009.03.042
Reddy, P. H., and Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and
synaptic damage: implications for cognitive decline in aging and Alzheimer’s
disease. Trends Mol. Med. 14, 45–53. doi: 10.1016/j.molmed.2007.12.002
Reddy, P. H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T. P., Anekonda, V.,
et al. (2012). Abnormal mitochondrial dynamics and synaptic degeneration
as early events in Alzheimer’s disease: implications to mitochondria-
targeted antioxidant therapeutics. Biochim. Biophys. Acta 1822, 639–649.
doi: 10.1016/j.bbadis.2011.10.011
Rui, Y., Tiwari, P., Xie, Z., and Zheng, J. Q. (2006). Acute impairment of
mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons.
J. Neurosci. 26, 10480–10487. doi: 10.1523/JNEUROSCI.3231-06.2006
Sheng, Z. H., and Cai, Q. (2012). Mitochondrial transport in neurons: impact on
synaptic homeostasis and neurodegeneration. Nat. Rev. Neurosci. 13, 77–93.
doi: 10.1038/nrn3156
Skulachev, V. P. (2001). Mitochondrial filaments and clusters as
intracellular power-transmitting cables. Trends Biochem. Sci. 26, 23–29.
doi: 10.1016/S0968-0004(00)01735-7
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S.
L., et al. (2005). Axonopathy and transport deficits early in the pathogenesis of
Alzheimer’s disease. Science 307, 1282–1288. doi: 10.1126/science.1105681
Takuma, K., Fang, F., Zhang, W. S., Yan, S. Q., Fukuzaki, E., Du, H., et al. (2009).
RAGE-mediated signaling contributes to intraneuronal transport of amyloid-
beta and neuronal dysfunction. Proc. Natl. Acad. Sci. U.S.A. 106, 20021–20026.
doi: 10.1073/pnas.0905686106
Umeda, T., Ramser, E. M., Yamashita, M., Nakajima, K., Mori, H., Silverman, M.
A., et al. (2015). Intracellular amyloid beta oligomers impair organelle transport
and induce dendritic spine loss in primary neurons. Acta Neuropathol.
Commun. 3, 51. doi: 10.1186/s40478-015-0230-2
Verstreken, P., Ly, C. V., Venken, K. J., Koh, T. W., Zhou, Y., and Bellen,
H. J. (2005). Synaptic mitochondria are critical for mobilization of reserve
pool vesicles at Drosophila neuromuscular junctions. Neuron 47, 365–378.
doi: 10.1016/j.neuron.2005.06.018
Yang, J., Seo, J., Nair, R., Han, S., Jang, S., Kim, K., et al. (2011). DGKiota regulates
presynaptic release during mGluR-dependent LTD. EMBO J. 30, 165–180.
doi: 10.1038/emboj.2010.286
Yin, F., Liu, J., Ji, X., Wang, Y., Zidichouski, J., and Zhang, J. (2011).
Silibinin: a novel inhibitor of Abeta aggregation. Neurochem. Int. 58, 399–403.
doi: 10.1016/j.neuint.2010.12.017
Zeng, Y., Zhang, J., Zhu, Y., Zhang, J., Shen, H., Lu, J., et al. (2015). Tripchlorolide
improves cognitive deficits by reducing amyloid beta and upregulating synapse-
related proteins in a transgenic model of Alzheimer’s Disease. J. Neurochem.
133, 38–52. doi: 10.1111/jnc.13056
Zhang, Y., Yin, F., Liu, J., Liu, Z., Guo, L., Xia, Z., et al. (2015). Geniposide
attenuates insulin-deficiency-induced acceleration of beta-amyloidosis in an
APP/PS1 transgenic model of Alzheimer’s disease. Neurochem. Int. 89, 7–16.
doi: 10.1016/j.neuint.2015.04.002
Zhao, C., Lv, C., Li, H., Du, S., Liu, X., Li, Z., et al. (2016a). Geniposide
protects primary cortical neurons against oligomeric Aβ1−42-induced
neurotoxicity through a mitochondrial pathway. PLoS ONE 11:e0152551.
doi: 10.1371/journal.pone.0152551
Zhao, C., Zhang, H., Li, H., Lv, C., Liu, X., Li, Z., et al. (2016b).
Geniposide ameliorates cognitive deficits by attenuating the
cholinergic defect and amyloidosis in middle-aged Alzheimer model
mice. Neuropharmacology 11, 18–29. doi: 10.1016/j.neuropharm.
2016
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Zhang, Zhao, Lv, Liu, Du, Li, Wang and Zhang. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 13 January 2017 | Volume 10 | Article 309
